IPSC NASDAQ
Century Therapeutics, Inc.
1W: -8.4%
1M: -27.5%
3M: -36.2%
YTD: +53.8%
1Y: +206.1%
3Y: -24.3%
5Y: -93.4%
$1.53
-0.08 (-4.97%)
Weekly Expected Move ±6.8%
$1
$1
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships6
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-01-10
Earliest Filing
2024-04-11
Latest Filing
partner: 5
target: 1
Counterparties (Filed by IPSC)
6 relationshipsCompanies named in IPSC's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Clade Therapeutics, Inc. | CLAD | target | Target of merger agreement and acquisition completed on April 11, 2024. | 2024-04-11 | View |
| Fortis Advisors LLC | — | partner | Acted as Securityholders' Agent in the Agreement and Plan of Merger. | 2024-04-11 | View |
| Cowen and Company, LLC | — | partner | Sales agent for the at-the-market offering of common stock | 2022-07-01 | View |
| FUJIFILM Cellular Dynamics Inc. | — | partner | Exclusive and non-exclusive licensee for iPSC differentiation and reprogramming patents | 2022-01-13 | View |
| Bristol-Myers Squibb Company | — | partner | Collaborator for cancer immunotherapeutics with sublicensing rights in Japan | 2022-01-13 | View |
| Bristol-Myers Squibb Company | BMY | partner | Partnered with Century Therapeutics for research, development, and commercialization of cell therapy programs; purchased | 2022-01-10 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-02 | Regulation FD; Other Events; Exhibits | View | |
| 2026-09-09 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-08-12 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-06-16 | Officer/Director Change | View | |
| 2026-06-12 | Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-06-08 | Other Events; Exhibits | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-03-26 | Other Events; Exhibits | View | |
| 2026-03-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-23 | Submission of Matters to a Vote of Security Holders; Other Events | View | |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-08 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-12-29 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-12-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-09 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2025-08-29 | Notice of Delisting or Transfer | View | |
| 2025-08-14 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-07-07 | Costs Associated with Exit or Disposal Activities; Departure/Election of Directors; Appointment of O | View | |
| 2025-06-16 | Submission of Matters to a Vote of Security Holders | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR